|
Synonyms: epcoritamab-bysp | Epkinly® | GEN-3013 | GEN3013 | Tepkinly®
epcoritamab is an approved drug (FDA & EMA (2023))
Compound class:
Antibody
Comment: Epcoritamab (GEN3013) is a novel CD3ε/CD20 bispecific IgG1 antibody that redirects CD3+ cytotoxic T cells to selectively destroy CD20+ve malignant B cells [1-2]. Its Fc domain has been mutated to prevent FcγR and complement binding.
|
| Immunopharmacology Comments |
| Engages T cells towards CD20 positive tumour cells to enhance the anti-tumour immune response. |
